MA39818A - Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques - Google Patents

Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques

Info

Publication number
MA39818A
MA39818A MA039818A MA39818A MA39818A MA 39818 A MA39818 A MA 39818A MA 039818 A MA039818 A MA 039818A MA 39818 A MA39818 A MA 39818A MA 39818 A MA39818 A MA 39818A
Authority
MA
Morocco
Prior art keywords
cancer
oncolytic viruses
armed
cells
tap inhibitor
Prior art date
Application number
MA039818A
Other languages
English (en)
Inventor
Ram Aiyar
Steven Fuhrmann
Matthew Mulvey
Original Assignee
Benevir Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benevir Biopharm Inc filed Critical Benevir Biopharm Inc
Publication of MA39818A publication Critical patent/MA39818A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des virus oncolytiques armés comprenant un inhibiteur de tap exogène qui se répliquent sélectivement dans des cellules cancéreuses, évitent les lymphocytes t cytolytiques cd8+, et induisent le système immunitaire à reconnaître les cellules tumorales. L'invention concerne également des compositions et des méthodes thérapeutiques faisant appel aux virus oncolytiques, notamment des compositions et des méthodes thérapeutiques permettant de traiter des cancers, tels qu'un mélanome, un cancer de la tête et du cou, un cancer de l'ovaire, un cancer du sein, un glioblastome, un cancer de la vessie, un cancer de la prostate, un cancer du poumon, un cancer du foie, un cancer colorectal, un cancer du pancréas, et un cancer rénal.
MA039818A 2014-03-30 2014-03-30 Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques MA39818A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972327P 2014-03-30 2014-03-30

Publications (1)

Publication Number Publication Date
MA39818A true MA39818A (fr) 2017-02-08

Family

ID=52875293

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039818A MA39818A (fr) 2014-03-30 2014-03-30 Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques

Country Status (5)

Country Link
US (1) US10232003B2 (fr)
EP (1) EP3125911A1 (fr)
CA (1) CA2944278A1 (fr)
MA (1) MA39818A (fr)
WO (1) WO2015153417A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105343877B (zh) * 2015-11-26 2019-03-01 中国兽医药品监察所 一种5基因缺失伪狂犬病重组病毒活疫苗及其制备方法
WO2017118866A1 (fr) 2016-01-08 2017-07-13 Replimune Limited Virus modifié
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RU2742726C2 (ru) * 2016-12-09 2021-02-10 Генемедицине Ко., Лтд. Противораковая композиция, содержащая рекомбинантный аденовирус, экспрессирующий разрушающий фактор для внеклеточного матрикса
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
AU2018228308B2 (en) 2017-02-28 2022-01-27 Genemedicine Co., Ltd. Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor
WO2018161092A1 (fr) * 2017-03-03 2018-09-07 New York University Induction et amélioration de l'immunité antitumorale impliquant des vecteurs viraux exprimant de multiples épitopes d'antigènes associés à une tumeur et d'inhibiteurs de points de contrôle immunitaires ou de protéines
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) * 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
US20240238616A1 (en) * 2021-05-26 2024-07-18 The Jackson Laboratory Radiosensitizing compositions and methods
WO2024124190A1 (fr) 2022-12-09 2024-06-13 Microbial Machines, Inc. Micro-organismes modifiés pour l'administration d'agents thérapeutiques
CN120787263A (zh) * 2022-12-20 2025-10-14 詹森生物科技公司 溶瘤病毒及其用途
WO2024263805A1 (fr) 2023-06-21 2024-12-26 Microbial Machines, Inc. Micro-organismes génétiquement modifiés pour la détection de cellules malades

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2629818B1 (fr) 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
US5071743A (en) 1989-10-27 1991-12-10 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Process for conducting site-directed mutagenesis
FR2662441B1 (fr) 1990-05-22 1992-10-23 Rhone Poulenc Sante Procede de preparation enantioselective de derives de la phenylisoserine.
FR2662440B1 (fr) 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
JP3442774B2 (ja) 1991-07-01 2003-09-02 バーレックス ラボラトリーズ，インコーポレイティド 新規な突然変異誘発法および組成物
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5750398A (en) 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6242222B1 (en) 1996-06-07 2001-06-05 Massachusetts Institute Of Technology Programmed sequential mutagenesis
US5780270A (en) 1996-07-17 1998-07-14 Promega Corporation Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
EP0966301B1 (fr) 1996-07-31 2005-02-09 Ortho-McNeil Pharmaceutical, Inc. Identification de genes du cytomegalovirus humain impliques dans la retro-regulation de l'expression des chaines lourdes de classe i du cmh
SE9604581D0 (sv) 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
ATE312189T1 (de) 2000-01-21 2005-12-15 Biovex Ltd Virusstämme für die onkolytische behandlung von krebs
ES2366608T3 (es) 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.
US7730087B2 (en) 2003-02-28 2010-06-01 Raining Data Corporation Apparatus and method for matching a query to partitioned document path segments
WO2005118825A2 (fr) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Adenovirus chimeres a utiliser dans le traitement du cancer
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20100092435A1 (en) 2006-12-07 2010-04-15 Emmanuel Jacques Henri Joseph Wiertz Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teipp
WO2009008713A1 (fr) 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Inhibiteurs de tap à partir d'herpèsvirus 1 de primate d'europe et leur utilisation
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
EP3333265B1 (fr) 2010-05-14 2020-02-05 Oregon Health & Science University Vecteurs hcmv et rhcmv recombinants qui encodent un antigène hétérologue du virus de l'hepatite b et leurs utilisations
WO2012089225A1 (fr) 2010-12-29 2012-07-05 Curevac Gmbh Combinaison de vaccination et d'inhibition de la présentation des antigènes restreinte par le cmh de classe i
HRP20182194T1 (hr) 2011-09-08 2019-02-22 New York University Onkolitički herpes simpleks virus i njegova terapeutska uporaba

Also Published As

Publication number Publication date
WO2015153417A1 (fr) 2015-10-08
US20170173092A1 (en) 2017-06-22
US10232003B2 (en) 2019-03-19
CA2944278A1 (fr) 2015-10-08
EP3125911A1 (fr) 2017-02-08

Similar Documents

Publication Publication Date Title
GB2557123A (en) Modified cells and methods of therapy
EP4691562A3 (fr) Combinaisons anti-pd-l1 pour le traitement de tumeurs
TW201613648A (en) Compounds and compositions for immunotherapy
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2019008196A (es) Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales.
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
GB2573406A (en) Tumor infiltrating lymphocytes and methods of therapy
PH12017500634A1 (en) Compositions and methods of use for augmented immune response and cancer therapy
EP3964527A3 (fr) Polythérapie contre le cancer
SG10202001660YA (en) Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
IL256160A (en) New peptides and their combination for use in immunotherapy and methods for creating scaffolds for use against pancreatic cancer and other types of cancer
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
TW201613966A (en) SynTac polypeptides and uses thereof
MX374472B (es) Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
WO2018102589A3 (fr) Anticorps anti-hrs et polythérapies pour le traitement de cancers
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
EP4599893A3 (fr) Cg0070 pour le traitement in situ du carcinome de la vessie résistant à bcg
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2015013021A (es) 5-bromo-indirrubinas.